You just read:

Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis

News provided by

Tarsa Therapeutics, Inc.

Mar 24, 2011, 07:30 ET